MedWorm: Urology & Nephrology Clinical Trials

Communicating About Choices in Transplantation

ClinicalTrials.gov — Tue, 07 May 2013 16:00:00 +0100

Condition: End Stage Renal Disease and Kidney TransplantationIntervention: Behavioral: COACH ProgramSponsors: Virginia Commonwealth University; Virginia Commonwealth University; Health Resources and Services Administration (HRSA)Not yet recruiting - verified May 2013 (Source: ClinicalTrials.gov)

MedWorm Sponsor Message: In Bahrain prison they have restricted water intake of human rights defender + kidney stone sufferer Nabeel Rajab to 6 litres a week.

Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1

ClinicalTrials.gov — Sun, 14 Apr 2013 16:00:00 +0100

Condition: Postmenopausal OsteoporosisIntervention: Drug: Liuwei Dihuang PillsSponsors: Fujian Institute Of Trational Chinese Medicine; Fujian Institute Of Trational Chinese MedicineRecruiting - verified April 2013 (Source: ClinicalTrials.gov)

The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)

ClinicalTrials.gov — Fri, 12 Apr 2013 16:00:00 +0100

Condition: Non Alcoholic Fatty Liver DiseaseInterventions: Behavioral: Unsupervised exercise training; Behavioral: Supervised exercise trainingSponsors: University of Liverpool; University of Liverpool; Royal Liverpool University Hospital; University of Surrey; Imperial College London; Royal Surrey County HospitalActive, not recruiting - verified April 2013 (Source: ClinicalTrials.gov)

RAS Quantification in Patients With Aliskiren or Candesartan

ClinicalTrials.gov — Thu, 04 Apr 2013 16:00:00 +0100

Conditions: Hypertension; Chronic Kidney Disease; ProteinuriaInterventions: Other: RAS blockade discontinuation; Drug: Aliskiren; Drug: CandesartanSponsors: Medical University of Vienna; Medical University of ViennaRecruiting - verified April 2013 (Source: ClinicalTrials.gov)

MedWorm Sponsor Message: In Bahrain prison they have restricted water intake of human rights defender + kidney stone sufferer Nabeel Rajab to 6 litres a week.

Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension

ClinicalTrials.gov — Thu, 21 Mar 2013 16:00:00 +0100

Conditions: Hypertension; Chronic Kidney DiseaseIntervention: Procedure: Renal sympathetic denervationSponsors: UMC Utrecht; UMC Utrecht; ZonMw: The Netherlands Organisation for Health Research and Development; MedtronicNot yet recruiting - verified May 2013 (Source: ClinicalTrials.gov)

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

ClinicalTrials.gov — Tue, 19 Mar 2013 16:00:00 +0100

Condition: Type 1 Diabetes MellitusInterventions: Procedure: Euglycemic clamp (normal blood sugar clamp) for 4 hours; Procedure: hyperglycemic clamp (elevated blood sugar to 300) for 4 hoursSponsors: University of Michigan; University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting - verified March 2013 (Source: ClinicalTrials.gov)

Dose-finding Study of MCI-196

ClinicalTrials.gov — Mon, 18 Mar 2013 16:00:00 +0100

Conditions: Chronic Kidney Disease; Dialysis; Hyperphosphatemia; PaediatricInterventions: Drug: colestilan-L; Drug: colestilan-M; Drug: colestilan-H; Drug: CBPBSponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma CorporationNot yet recruiting - verified March 2013 (Source: ClinicalTrials.gov)

Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure

ClinicalTrials.gov — Fri, 08 Mar 2013 17:00:00 +0100

Condition: Renal Transplant Patients After Return to DialysisInterventions: Procedure: Transplantectomy within two months after return to dialyse; Procedure: Progressive reduction of immunosuppression. Transplantectomy for cause onlySponsors: Hospices Civils de Lyon; Hospices Civils de LyonRecruiting - verified March 2013 (Source: ClinicalTrials.gov)

Data Demonstrating the Safety and Efficacy of Chimerix's Antiviral CMX001 Presented at BMT Tandem Meetings

Drugs.com - Clinical Trials — Mon, 25 Feb 2013 18:50:24 +0100

- No evidence of CMX001-associated kidney toxicity was seen in stem cell transplant recipients who were enrolled in a 230-patient Phase 2 study to evaluate CMX001 for prevention of cytomegalovirus (CMV) infection. Subjects on CMX001 had stable to... (Source: Drugs.com - Clinical Trials)

Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients

ClinicalTrials.gov — Mon, 25 Feb 2013 17:00:00 +0100

Conditions: Sepsis; Acute Kidney InjuryIntervention: Sponsors: University of Chile; University of ChileRecruiting - verified February 2013 (Source: ClinicalTrials.gov)

HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems

Drugs.com - Clinical Trials — Thu, 21 Feb 2013 15:02:31 +0100

CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three... (Source: Drugs.com - Clinical Trials)

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

Drugs.com - Clinical Trials — Wed, 13 Feb 2013 12:48:18 +0100

Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Feb 12, 2013 - AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced... (Source: Drugs.com - Clinical Trials)

MedWorm Sponsor Message: In Bahrain prison they have restricted water intake of human rights defender + kidney stone sufferer Nabeel Rajab to 6 litres a week.

Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease.

ClinicalTrials.gov — Mon, 11 Feb 2013 17:09:33 +0100

Conditions: Alcoholism; Liver Disease; Liver FibrosisIntervention: Other: liver biopsieSponsors: Rennes University Hospital; Rennes University HospitalRecruiting - verified January 2013 (Source: ClinicalTrials.gov)

Hepatology Publishes 12-Week Phase I/II Extension Study Data of Sebelipase Alfa in Adults with Late Onset LAL Deficiency

Drugs.com - Clinical Trials — Tue, 05 Feb 2013 19:35:17 +0100

- Sebelipase alfa improves markers of liver damage and dyslipidemia associated with LAL Deficiency- LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 4, 2013 - Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company... (Source: Drugs.com - Clinical Trials)

BioSpecifics Technologies Corp. Announces Online Publication in The Journal of Urology of Results from the IMPRESS Trials of XIAFLEX in Peyronie's Disease

Drugs.com - Clinical Trials — Tue, 05 Feb 2013 19:10:20 +0100

LYNBROOK, N.Y., Feb. 4, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia,... (Source: Drugs.com - Clinical Trials)

Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome

ClinicalTrials.gov — Tue, 05 Feb 2013 17:00:00 +0100

Condition: Irritable Bowel SyndromeInterventions: Drug: Dronabinol; Drug: PlaceboSponsors: Mayo Clinic; Michael Camilleri; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Center for Research Resources (NCRR)Completed - verified February 2013 (Source: ClinicalTrials.gov)

Celsion Announces Results of Phase III HEAT Study of ThermoDox in Primary Liver Cancer

Drugs.com - Clinical Trials — Thu, 31 Jan 2013 12:22:10 +0100

Company to Host Conference Call at 8:00 AM EST Today LAWRENCEVILLE, N.J., Jan. 31, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that ThermoDox® in combination... (Source: Drugs.com - Clinical Trials)

Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer

Drugs.com - Clinical Trials — Wed, 30 Jan 2013 13:26:19 +0100

- Results Published in Cancer Discovery Document Most Comprehensive Human Experience To Date for RNAi Therapeutics Delivered with Lipid Nanoparticles (LNPs) - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 30, 2013 - Alnylam Pharmaceuticals, Inc. (Nasdaq:... (Source: Drugs.com - Clinical Trials)

Ultrasound Based Acoustic Radiation Force Impulse, Shear Wave Velocity Imaging in Pediatric Patients Undergoing Liver Biopsy

ClinicalTrials.gov — Tue, 29 Jan 2013 17:00:00 +0100

Conditions: Liver Fibrosis; Liver InflammationIntervention: Device: Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)Sponsors: University of Michigan; University of MichiganRecruiting - verified January 2013 (Source: ClinicalTrials.gov)

New England Journal of Medicine Publishes Pivotal Trial Data for OMONTYS (peginesatide) Injection for Treatment of Anemia in Adult Chronic Kidney Disease Patients on Hemodialysis

Drugs.com - Clinical Trials — Thu, 24 Jan 2013 20:07:15 +0100

-- Head-to-Head Comparison of Efficacy of Erythropoiesis-Stimulating Agents, Including First Prospective Cardiovascular Safety Assessment -- PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Jan 23, 2013 - Affymax, Inc. (Nasdaq:AFFY) and... (Source: Drugs.com - Clinical Trials)

MedWorm Sponsor Message: In Bahrain prison they have restricted water intake of human rights defender + kidney stone sufferer Nabeel Rajab to 6 litres a week.

Cellmid Records Positive Data in Midkine Antibody Study in Kidney Disease

Drugs.com - Clinical Trials — Thu, 24 Jan 2013 12:20:42 +0100

• Anti-midkine antibodies reduced mortality rate and preserved kidney function in a mouse model of diabetic nephropathy • Kidney damage markedly reduced in treated animals • Additional data bolsters preclinical antibody... (Source: Drugs.com - Clinical Trials)

NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients

ClinicalTrials.gov — Fri, 18 Jan 2013 17:19:54 +0100

Condition: Kidney TransplantationIntervention: Other: Blood drawingSponsors: University of California, San Francisco; University of California, San Francisco; Astellas Pharma IncRecruiting - verified January 2013 (Source: ClinicalTrials.gov)

Phase III Data in The Lancet Show Significant Benefit of Novartis Drug Afinitor in Patients with Non-cancerous Tumors Associated with TSC

Drugs.com - Clinical Trials — Fri, 11 Jan 2013 11:32:51 +0100

- More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression(1) - Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half... (Source: Drugs.com - Clinical Trials)

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

ClinicalTrials.gov — Thu, 10 Jan 2013 17:00:00 +0100

Conditions: Abnormal Glucose Tolerance; Type 1 DiabetesInterventions: Drug: CTLA4-Ig (Abatacept); Drug: PlaceboSponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); American Diabetes Association; Juvenile Diabetes Research FoundationNot yet recruiting - verified January 2013 (Source: ClinicalTrials.gov)

"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".

ClinicalTrials.gov — Fri, 04 Jan 2013 17:14:21 +0100

Conditions: Latent Tuberculosis Infection; Infection in Solid Organ Transplant RecipientsInterventions: Drug: Levofloxacin; Drug: IsoniazidSponsors: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla; Fundación Pública Andaluza para la gestión de la Investigación en Sevilla; Spanish Network for Research in Infectious DiseasesRecruiting - verified January 2013 (Source: ClinicalTrials.gov)